Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OUCH!!!!
S.C.A.M P.O.N.Z.I VENOM?
I think the trick part is when you said: “This w his own money “ … By saying “This w his own money “ what exactly do you mean? I did hear him saying at the beginning stage he was paying certain things out of his pockets, during financial updates. Now this is the technology expansion update, he never said anything about paying from his pockets on this phase level. This is serious!!! Find anywhere in his CC, statements, where he claimed that he will pay “all” from his pockets!!! Since we’re clear on this point, I believe you made up such. I am not saying, he is the greatest CEO ever, I am just clarifying your statement for the public
This is a sign SB is moving forward with the HPIL projects... However, I am concern because this is what we call a toxic debt in OTC, 2nd we do not know the payback terms of such and lastly I am still concern he never explained what is going to be the end path of the O/S and A/S... Is this 10M related to what's coming with the the 60B AS? We gotta keep the eyes open. 10M is a lot of money BUT , AGAIN, if it is invested wisely: HPIL will be INCREDIBLE
Come On Dr. Koos!!! Drop it more like it is hot!!! I want to buy more cheapies!!! I want this to touch the 1c level
I cant wait to add more at the penny level!!!! I have 10K ready for it!!!
YEAHH!!! I added more into my arsenal!!! So much happiness I was capable to add more to these levels. Very excited, if it drop more, I have $10K to add more in intervals 0.02 cents 5K and maybe 5K more if it drops lower... A BARGAIN
He is already BIG Stephen. He is being called by some people in twitter Commander In Chief, Spartan SB
Considering the important role a CSO must be, and how smart Dr. Koos has proven to be, I am not surprised if it takes too long to find an excellent CSO. Only a naive and desperate CEO will hire someone on the flush of a toilet AND this is not the case, of course. Why would someone assume such?
Naah, HUMBLE and ASTA got their name changed faster than a thunder, this depends of the CEO, the company board team and the financial issues and potential lawsuit a company could have before considering a name change. Every case is different, Medolife is an international company, they have to cover their bases before jumping the broom. I am not surprised they have taken this long, it is a big company
Global Anemia Drugs Market 2021 Business Strategies – GlaxoSmithKline, Global Blood Therapeutics (GBT), Bluebird Bio, GlycoMimetics
Photo of david davidOctober 1, 2021 49
Anemia Drugs Market Share, Trends, Segmentation and Forecast by 2025 | CAGR of 11.20% | Medgadget
Market Research Place released a report on Global Anemia Drugs Market from 2021 to 2027. The study has been conducted based on several analytical and theoretical data to provide organizations in making their business strategies. The information is very important for market competitors who are entering in the market. The information gathered from various sources some are from annual reports some from competitor’s website and articles.
The study gives the precise knowledge of Anemia Drugs market to understand its Type and Applications. Type gives a thorough understanding of report which is deeply dived into the advantages and developments done in near future. The study also focuses on market end users, products & specifications.
DOWNLOAD FREE SAMPLE REPORT: https://www.marketresearchplace.com/report-detail/203383/request-sample
Another segment included in the report are key competitors & the market also include the study based upon the territory which is further sub divided into countries across globe. It gives a clear picture of Anemia Drugs market. As a result, the study offers buyers with a comprehensive understanding of the market using specific approach which will help the to grow the business appropriately.
Company profiles is one of the major factors covered in this report. The study covers all the major manufacturers of Anemia Drugs and offers an in-dept analysis on their products, market share, volumes, prices, revenues, profits, growth rate and future projections. This data ensures in doing a thorough competitor analysis thus coming up with different strategies ahead of penetrating the market.
The list of key players included in this report are
GlaxoSmithKline
Global Blood Therapeutics (GBT)
Bluebird Bio
GlycoMimetics
Mast Therapeutics
Fibrogen
Akebia Therapeutics
Bayer AG
Eli Lilly
Regen Biopharma
Acceleron Pharma
Celgene Corporation
Onconova Therapeutics
Pieris Pharmaceuticals
While performing analysis on the company profiles, the analysts have also covered the different products launched by these players. This data point let into covering the different types and applications of the Anemia Drugs.
The different types of Anemia Drugs covered in this report include
Oral
Injection
The list of applications covered in this study include
Iron Deficiency Anemia
Chronic Kidney Disease related Anemia
Sickle Cell Anemia
Aplastic Anemia
ACCESS FULL REPORT: https://www.marketresearchplace.com/report/global-anemia-drugs-market-research-report-2021-2027-203383.html
With the ease of doing global business and rising international trades, it is very important to carrying out a global research while studying the market. This report covers all the major regions as well as major countries.
The list of countries covered in this report are
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@marketresearchplace.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.
Contact Us
Mark Stone
Head of Business Development
Phone: +1-201-465-4211
Email: sales@marketresearchplace.com
Ongoing Agreement With Eli Lilly Leads to Discovery of Several New Small Molecule Drugs
$RGBP - Regen BioPharma, Inc. (OTCQBRGBP & RGBPP)
Summary:
Eli Lilly Agreement
Milestones Surpassed
Developing New Small Molecule Drugs
Cancer
Lupus
The compounds, thousands upon thousands Regen has tested are Provided by Eli Lilly and Co. ( LLY ) via a Collaborative Agreement that States - Eli Lilly has the Right to License or Purchase Any/All Developed Compounds and New Drugs.
Recently Regen announced Two New Milestones that have led to the Discovery of Several New Small Molecule Drugs that have potential Cancer-Killing effects and Proven success treating Lupus.
Cancer Treatment
They Have Identified a Series of Small Molecule Drugs that Inhibit NR2F6 & also Activate Human Immune Cells ex-vivo.
Evidence has been provided by studies suggesting the new drugs Repress the Body's Immune Response Against Tumors and activate T-Cells that have potential Cancer-Killing Effects.
While Preliminary these Results are Extremely Encouraging. The Agonists are Behaving as Regen Hoped & Expected They Would. These are very exciting times at Regen as the make major leaps now in progress with their program for Cancer treatment.
Autoimmune Therapies
Regen also reported success with their Small Molecule Program and Drugs that inhibit NR2F6 and the treatment of Autoimmune Diseases recently.
Their screening process demonstrated that they have identified the NR2F6 nuclear receptor as a potential, very important immune cell inhibitor (an immune checkpoint). This is critical in developing therapies for treating autoimmune diseases.
These novel chemical compounds have shown success and the potential for treating autoimmune diseases such as Lupus. Regen's Lead Drug Candidate, RG-NAE005 was tested for the maximum dosage and showed no signs of toxicity, or cytotoxicity. This exhibited as a single dose of 2,000 mg/kg and repeated doses of 400 mg/kg.
This is very exciting, as it indicates that the drug will likely be safe in animals as they move forward and begin the efficacy phase of trials.
We think RGBP is a Long Play with Short Term Gain Potential. The Support and Volume has increased and it has shown the potential to bounce up. Recently over 100%. It has retraced giving back all that it gained. Profit taking and more than likely the maturation of Debt Equity financing. Could be an opportunity at this level for new investors, or cost averaging for existent shareholders.
Keep in mind Eli Lilly reserves the right to license and or purchase any compounds developed, and/or new drugs. Regen could be an attractive merge-buyout target at some point.
You Will Find All of the News-Press Releases-Filings & Supporting Information at these Sites:
https://www.regenbiopharmainc.com
https://www.otcmarkets.com/stock/RGBP/overview
https://finance.yahoo.com/quote/RGBP?ltr=1
I was thinking the same. I am not letting my shares alone for any second. Protecting them with my shield!!! Spartan way. When the time comes, it is going to be fast and wild!!!
OUCHHHHHH
That's kind of what I have been saying for a while. I am not betting on the company, I am betting on his bluff or not. He is not a traditional CEO, I did observe several times his CC videos and the man seem authentic. I do not think he is Con Artist type. He is facing everyone, Con Artist normally avoid certain battles, this guy does not. He already paid lots of money to bring this company current, a con artist would not get this far, unless he believes there is more to it but still, the company is real, financial intel has been submitted. We just gotta wait, plus look at the NFT deal, we are going to have free shares (Nobody saw this coming) let them rain over us. We will be fine
I don’t agree with him that much either but I recognize a truth from a mile. I have been saying to be careful in here, wait for the CEO himself to speak up. There are lots of professional pumpers and con artists around Enzo, some of the articles provided have lots to explain yet and pumpers are good on twisting facts around. Don’t go ahead of yourself and be careful buying around these prices. This is still an Wolf Territory… Sheep always gets eaten in here
We are surrounded of penny seekers and day traders in here. Ohh way, monthly rent is up, about to get ugly./// I am holding LONG...
If you do not have the skin for non LT, yeah go ahead but it is always wise to check both versions. This is a very speculative stock, it is good always to check both negative smart responses and LT fanatics too.
Hopefully this gets more clear tomorrow in the CC. I only hope he makes great this time AND of course, I asked by email what is he planning to do with such outrageous O/S and A/S numbers.
Hahahaha, don't you think I know that? lol
KABOOM!!! Well said comrade, well put...
If Enzo made it to 0.96 cents once, I am just curious what HPIL could accomplish in this quarter
Been an while since I don't see some providing a statement like yours in here.... Best wishes for you as well and I am totally with you. October will be epic and now that Dr. Koos will keep us updated in the loop is outstanding... I am long in here as well, until the dollar land. Loyal til the end
Bananas
Me too, I am buying more... This is my early retirement investment...
why are you saying so? Because the stock didnt skyrocket according to you!!! Please share your point!!! You are welcomed to do so.. You definitely have something to say:
This is going to be huge people, keep holding. Free money now by this NTF deal
So, we are going to get STGZ shares... Heey, 0.23 cents a share, free money I didn't see coming. Welcome... Now, let's see how this will be distributed to us and what SB gets out of this too. I am sure he gets his cut as well
Very nice...
Lucky you, I have been averaging up to 0.037 AND I keep buying more. I will buy more today
Totally agree with you. He shouldn't be doing those CC. Just a PR and call it the day
You shouldn't fear if you're long. Relax
They have been extended to those companies that are behind but still submitting paperwork. Those whose didn't submit anything are officially out now
If you are right, I am going to Tattoo my $$$$ with your name. LMAOOO... OTCQB on the making, this going to be huge
Why don’t you email him and ask yourself. If you know the answer, please share it with us… (We know you don’t know) Dr. Koos has been proving you, wrong!!! OTCQB in the making
It is a typo. 2 things, that has been there for months, and REGEN is a direct SEC filer not a OTCM direct filer. If this would be true, it would be disclosures in a file thru the SEC now
That section was written like that since 2019. I remember to have seen it like that a few months ago. OTCM didnt update such after the stepdown
I don't think so but if you read the 8K, Dr. Koos directly says OTCQB is coming soon, short term vision.
I am glad you did call him on this. He is obviously lost on this NDA term, if any on this company. Speculations so far. I am with you, thanks